Advanced searches left 3/3
Search only database of 8 mil and more summaries

Gilead Covid Treatment

Summarized by PlexPage
Last Updated: 02 July 2021

* If you want to update the article please login/register

General | Latest Info

Gilead Sciences on Monday set the price for remdesivir, its antiviral drug that can shorten hospitalization stays for individuals ill with coronavirus Disease 2019 from SARS - COV - 2 infection, at 520 vial, or 3120 per patient for typical treatment course, for those with private insurance. The price for those not covered by private insurance will be 390 per vial. The treatment course is 6 vials. The Fda approved the drug for Emergency Use in some patients and the company has applied for full approval. The Institute for Clinical and Economic Review last week said remdesivir would be cost - effective at a price range of 4580 to 5080 if it saved lives. However, news that inexpensive steroid, dexamethasone, which does not have patent, improves survival means remdesivir should be priced between 2520 and 2800, ICER say. In a statement posted on the company website, Gileads CEO, Daniel ODay, say, There is no playbook for how to price new Medicine in a pandemic. We are aware of significant responsibilities that come with pricing remdesivir, and need to be transparent in our decision. In normal times, he say, drugs would be priced according to savings they provide. He said that shortening hospitalization time by an average of 4 days would result in savings of 12 000 per patient. He also said that the company expects its investment to exceed 1 billion. Analysts at Royal Bank of Canada told Reuters they saw revenue potential of 2. 3 billion from drugs in 2020, helping to offset those development and distribution costs. But the consumer group, Patients for Affordable Drugs, criticize price, saying that taxpayers, through the National Institute of Allergy and Infectious Diseases, Fund COVID - 19 remdesivir trial and that the Institute expects to spend a minimum of 30 million on remdesivir studies by the end of 2020. It also cites earlier government spending when drugs were studied for Ebola. By contrast, & 8203; & 8203; i & 8203; & 8203; & 8203; n 127 poor or middle - income countries, Gilead is allowing generic makers to supply Drug; 2 countries are doing that for around 600 per treatment course. Another group, Pacific Business Group on Health, which represents employers ' concerns, also said in a statement sent to American Journal of manage Care that it has serious concerns with price, citing ICER analysis and taxpayer - back research support. It is another unfortunate example of drug manufacturers taking advantage of their monopolies to set prices at whatever level they want. It is also a worrisome indicator that they will exploit the COVID pandemic to maximize their profits at the expense of patients. The bottom line is that this adds to the financial burden on employers and their employees and families, many of whom are already struggling from the impact of the COVID pandemic, group say. Hhs is managing allocation of remdesivir to hospitals until the end of September through agreement with Gilead. The agency said Monday it has more than 500 000 treatment courses.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Download Fact Sheets Here:

The Secretary of the Department of Health and Human Services has declared a public health Emergency that justifies Emergency Use of VEKLURY to treat coronavirus disease 2019 caused by SARS - CoV - 2 infection. In response, US Food and Drug Administration has issued an Emergency Use Authorization for an unapproved product, VEKLURY, for treatment of COVID - 19. Veklury is an investigational drug that has not been approved by FDA for any use. It is not yet know if VEKLURY is safe and effective for treatment of COVID - 19. Distribution of VEKLURY has been authorized only for treatment of hospitalized patients with COVID - 19. This Use is authorized only for duration of declaration that circumstances exist justifying Authorization of Emergency Use, unless Authorization is terminated or revoked sooner. Fda issued this EUA, request by Gilead Sciences and based on their submitted data. The FDA Letter of Authorization for EUA is available here. Healthcare Providers should review the Fact Sheet for Healthcare Providers for Information on authorized use of VEKLURY and the mandatory requirements of EUA. Veklury must be administered intravenously. The optimal duration of treatment for COVID - 19 is unknown. Suggest dose durations under this EUA are described in the Fact Sheet for Healthcare Providers, available here.


What is Guillain-Barre syndrome?

There is no known cure for Guillain - Barre syndrome. However, some therapies can lessen the severity of illness and shorten recovery time. There are also several ways to treat complications of disease. Because of possible complications of muscle weakness, problems that can affect any paralyzed person and the need for sophisticated medical equipment, individuals with Guillain - Barre syndrome are usually admitted and treated in hospitals ' intensive care unit. There are currently two treatments commonly used to interrupt immune - related nerve damage. One is plasma exchange; other is high - dose immunoglobulin therapy. Both treatments are equally effective if they start within two weeks of onset of GBS symptoms, but immunoglobulin is easier to administer. Using both treatments in the same person has no proven benefit. In the process of plasma exchange, plastic tube called a catheter is inserted into persons veins, through which some blood is remove. Blood cells from the liquid part of blood are extracted and returned to the person. This technique seems to reduce the severity and duration of Guillain - Barre episode.S Plasma contains antibodies and PE removes some plasma; PE may work by removing bad antibodies that have been damaging nerves. Immunoglobulins are proteins that the immune system naturally makes to attack infecting organisms. Ivig therapy involves intravenous injections of these immunoglobulins. Immunoglobulins are developed from a pool of thousands of normal donors. When IVIg is given to people with GBS, result can be lessening of immune attack on the nervous system. Ivig can also shorten recovery time. Investigators believe this treatment also lowers the levels or effectiveness of antibodies that attack nerves by both diluting them with non - specific antibodies and providing antibodies that bind to harmful antibodies and take them out of commission. Anti - inflammatory steroid hormones called corticosteroids have also been tried to reduce the severity of Guillain - Barre syndrome. However, control clinical trials have demonstrated that this treatment is not effective. Supportive care is very important to address many complications of paralysis as the body recovers and damaged nerves begin to heal. Respiratory failure can occur in GBS, so close monitoring of persons breathing should be instituted initially. Sometimes a mechanical ventilator is used to help support or control breathing. The autonomic nervous system can also be disturb, causing changes in heart rate, blood pressure, toileting, or sweating. Therefore, person should be put on heart monitor or equipment that measures and tracks body function. Occasionally, GBS - related nerve damage can lead to difficulty handling secretions in the mouth and throat. In addition to person choking and / or drooling, secretions can fall into the airway and cause pneumonia. As individuals begin to improve, they are usually transferred from acute care hospital to rehabilitation setting. Here, they can regain strength, receive physical rehabilitation and other therapy to resume activities of daily living, and prepare to return to their pre - illness life. Complications in GBS can affect several parts of the body.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Sources

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

logo

Plex.page is an Online Knowledge, where all the summaries are written by a machine. We aim to collect all the knowledge the World Wide Web has to offer.

Partners:
Nvidia inception logo

© All rights reserved
2021 made by Algoritmi Vision Inc.

If you believe that any of the summaries on our website lead to misinformation, don't hesitate to contact us. We will immediately review it and remove the summaries if necessary.

If your domain is listed as one of the sources on any summary, you can consider participating in the "Online Knowledge" program, if you want to proceed, please follow these instructions to apply.
However, if you still want us to remove all links leading to your domain from Plex.page and never use your website as a source, please follow these instructions.